美国西奈山伊坎医学院Sacha Gnjatic团队发现，一组炎性细胞因子特征可预测COVID-19的严重程度和存活率。相关论文于2020年8月24日在线发表于国际学术期刊《自然—医学》。

Title: An inflammatory cytokine signature predicts COVID-19 severity and survival

Author: Diane Marie Del Valle, Seunghee Kim-Schulze, Hsin-Hui Huang, Noam D. Beckmann, Sharon Nirenberg, Bo Wang, Yonit Lavin, Talia H. Swartz, Deepu Madduri, Aryeh Stock, Thomas U. Marron, Hui Xie, Manishkumar Patel, Kevin Tuballes, Oliver Van Oekelen, Adeeb Rahman, Patricia Kovatch, Judith A. Aberg, Eric Schadt, Sundar Jagannath, Madhu Mazumdar, Alexander W. Charney, Adolfo Firpo-Betancourt, Damodara Rao Mendu, Jeffrey Jhang, David Reich, Keith Sigel, Carlos Cordon-Cardo, Marc Feldmann, Samir Parekh, Miriam Merad, Sacha Gnjatic

Issue&Volume: 2020-08-24

Abstract: Several studies have revealed that the hyper-inflammatory response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease severity and death. However, predictive biomarkers of pathogenic inflammation to help guide targetable immune pathways are critically lacking. We implemented a rapid multiplex cytokine assay to measure serum interleukin (IL)-6, IL-8, tumor necrosis factor (TNF)-α and IL-1β in hospitalized patients with coronavirus disease 2019 (COVID-19) upon admission to the Mount Sinai Health System in New York. Patients (n=1,484) were followed up to 41 d after admission (median, 8 d), and clinical information, laboratory test results and patient outcomes were collected. We found that high serum IL-6, IL-8 and TNF-α levels at the time of hospitalization were strong and independent predictors of patient survival (P<0.0001, P=0.0205 and P=0.0140, respectively). Notably, when adjusting for disease severity, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-α serum levels remained independent and significant predictors of disease severity and death. These findings were validated in a second cohort of patients (n=231). We propose that serum IL-6 and TNF-α levels should be considered in the management and treatment of patients with COVID-19 to stratify prospective clinical trials, guide resource allocation and inform therapeutic options.

DOI: 10.1038/s41591-020-1051-9

Source: https://www.nature.com/articles/s41591-020-1051-9